Fluocinolone acetonide 0.2 µg/day intravitreal implant in non-infectious uveitis affecting the posterior segment: EU expert user panel consensus-based clinical recommendations
Abstract Background Non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) is an inflammatory disease, which can significantly impair visual acuity if not adequately treated. Fluocinolone-acetonide sustained-release-0.2 µg/day intravitreal (FAc) implants are indicated for prevent...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2024-05-01
|
| Series: | Journal of Ophthalmic Inflammation and Infection |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12348-024-00402-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544369189945344 |
|---|---|
| author | Uwe Pleyer Carlos Pavesio Elisabetta Miserocchi Carsten Heinz Helen Devonport Víctor Llorenç Tomás Burke Vanda Nogueira Laurent Kodjikian Bahram Bodaghi |
| author_facet | Uwe Pleyer Carlos Pavesio Elisabetta Miserocchi Carsten Heinz Helen Devonport Víctor Llorenç Tomás Burke Vanda Nogueira Laurent Kodjikian Bahram Bodaghi |
| author_sort | Uwe Pleyer |
| collection | DOAJ |
| description | Abstract Background Non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) is an inflammatory disease, which can significantly impair visual acuity if not adequately treated. Fluocinolone-acetonide sustained-release-0.2 µg/day intravitreal (FAc) implants are indicated for prevention of relapse in recurrent NIU-PS. The aim here was to provide treating clinicians with some consensus-based-recommendations for the clinical management of patients with NIU-PS with 0.2 µg/day FAc implants. Methods A European-clinical-expert-group agreed to develop a consensus report on different issues related to the use of FAc implants in patients with NIU-PS. Results The Clinical-expert-panel provided specific recommendations focusing on clinical presentation (unilateral/bilateral) of the NIU-PS; systemic involvement of NIU-PS and the lens status. Treatment algorithms were developed; one that refers to the management of patients with NIU-PS in clinical practice and another that establishes the best clinical scenarios for the use of FAc implants, both as monotherapy and as adjuvant therapy. Additionally, the Clinical-expert-panel has provided recommendations about the use of the FAc implants in a clinical-setting. The Clinical-expert-panel also considered the safety profile of FAc implants and their possible implications in the daily practice. Conclusions As more clinical experience has been gained using FAc implants, it was necessary to update the clinical recommendations that guide patient management in the clinic. The current consensus document addresses relevant issues related to the use of FAc implants on different types of patients with various etiologies of NIU-PS, and was conducted to standardize approaches to help specialists obtain better clinical outcomes. |
| format | Article |
| id | doaj-art-84770c02088e4f19842017f85c09c37f |
| institution | Kabale University |
| issn | 1869-5760 |
| language | English |
| publishDate | 2024-05-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Journal of Ophthalmic Inflammation and Infection |
| spelling | doaj-art-84770c02088e4f19842017f85c09c37f2025-01-12T12:35:22ZengSpringerOpenJournal of Ophthalmic Inflammation and Infection1869-57602024-05-0114111910.1186/s12348-024-00402-4Fluocinolone acetonide 0.2 µg/day intravitreal implant in non-infectious uveitis affecting the posterior segment: EU expert user panel consensus-based clinical recommendationsUwe Pleyer0Carlos Pavesio1Elisabetta Miserocchi2Carsten Heinz3Helen Devonport4Víctor Llorenç5Tomás Burke6Vanda Nogueira7Laurent Kodjikian8Bahram Bodaghi9Charité – Universitätsmedizin BerlinDepartment of Ophthalmology at Moorfields Eye HospitalDepartment of Ophthalmology, Ocular Immunology and Uveitis Service, University Vita-Salute, IRCCS San Raffaele Scientific InstituteDepartment of Ophthalmology at St, Franziskus Hospital MuensterBradford Teaching Hospitals NHS Foundation TrustClínic Hospital of BarcelonaDepartment of Ophthalmology, Mater Misericordiae University HospitalInstituto de Oftalmologia Dr. Gama PintoService d’Ophtalmologie, Hôpital Universitaire de La Croix-Rousse, Hospices Civils de LyonDepartment of Ophthalmology, Pitié-Salpêtrière HospitalAbstract Background Non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) is an inflammatory disease, which can significantly impair visual acuity if not adequately treated. Fluocinolone-acetonide sustained-release-0.2 µg/day intravitreal (FAc) implants are indicated for prevention of relapse in recurrent NIU-PS. The aim here was to provide treating clinicians with some consensus-based-recommendations for the clinical management of patients with NIU-PS with 0.2 µg/day FAc implants. Methods A European-clinical-expert-group agreed to develop a consensus report on different issues related to the use of FAc implants in patients with NIU-PS. Results The Clinical-expert-panel provided specific recommendations focusing on clinical presentation (unilateral/bilateral) of the NIU-PS; systemic involvement of NIU-PS and the lens status. Treatment algorithms were developed; one that refers to the management of patients with NIU-PS in clinical practice and another that establishes the best clinical scenarios for the use of FAc implants, both as monotherapy and as adjuvant therapy. Additionally, the Clinical-expert-panel has provided recommendations about the use of the FAc implants in a clinical-setting. The Clinical-expert-panel also considered the safety profile of FAc implants and their possible implications in the daily practice. Conclusions As more clinical experience has been gained using FAc implants, it was necessary to update the clinical recommendations that guide patient management in the clinic. The current consensus document addresses relevant issues related to the use of FAc implants on different types of patients with various etiologies of NIU-PS, and was conducted to standardize approaches to help specialists obtain better clinical outcomes.https://doi.org/10.1186/s12348-024-00402-4Fluocinolone intravitreal implantYutiqILUVIENIntraocular inflammationNon-infectious uveitisPosterior segment |
| spellingShingle | Uwe Pleyer Carlos Pavesio Elisabetta Miserocchi Carsten Heinz Helen Devonport Víctor Llorenç Tomás Burke Vanda Nogueira Laurent Kodjikian Bahram Bodaghi Fluocinolone acetonide 0.2 µg/day intravitreal implant in non-infectious uveitis affecting the posterior segment: EU expert user panel consensus-based clinical recommendations Journal of Ophthalmic Inflammation and Infection Fluocinolone intravitreal implant Yutiq ILUVIEN Intraocular inflammation Non-infectious uveitis Posterior segment |
| title | Fluocinolone acetonide 0.2 µg/day intravitreal implant in non-infectious uveitis affecting the posterior segment: EU expert user panel consensus-based clinical recommendations |
| title_full | Fluocinolone acetonide 0.2 µg/day intravitreal implant in non-infectious uveitis affecting the posterior segment: EU expert user panel consensus-based clinical recommendations |
| title_fullStr | Fluocinolone acetonide 0.2 µg/day intravitreal implant in non-infectious uveitis affecting the posterior segment: EU expert user panel consensus-based clinical recommendations |
| title_full_unstemmed | Fluocinolone acetonide 0.2 µg/day intravitreal implant in non-infectious uveitis affecting the posterior segment: EU expert user panel consensus-based clinical recommendations |
| title_short | Fluocinolone acetonide 0.2 µg/day intravitreal implant in non-infectious uveitis affecting the posterior segment: EU expert user panel consensus-based clinical recommendations |
| title_sort | fluocinolone acetonide 0 2 µg day intravitreal implant in non infectious uveitis affecting the posterior segment eu expert user panel consensus based clinical recommendations |
| topic | Fluocinolone intravitreal implant Yutiq ILUVIEN Intraocular inflammation Non-infectious uveitis Posterior segment |
| url | https://doi.org/10.1186/s12348-024-00402-4 |
| work_keys_str_mv | AT uwepleyer fluocinoloneacetonide02μgdayintravitrealimplantinnoninfectiousuveitisaffectingtheposteriorsegmenteuexpertuserpanelconsensusbasedclinicalrecommendations AT carlospavesio fluocinoloneacetonide02μgdayintravitrealimplantinnoninfectiousuveitisaffectingtheposteriorsegmenteuexpertuserpanelconsensusbasedclinicalrecommendations AT elisabettamiserocchi fluocinoloneacetonide02μgdayintravitrealimplantinnoninfectiousuveitisaffectingtheposteriorsegmenteuexpertuserpanelconsensusbasedclinicalrecommendations AT carstenheinz fluocinoloneacetonide02μgdayintravitrealimplantinnoninfectiousuveitisaffectingtheposteriorsegmenteuexpertuserpanelconsensusbasedclinicalrecommendations AT helendevonport fluocinoloneacetonide02μgdayintravitrealimplantinnoninfectiousuveitisaffectingtheposteriorsegmenteuexpertuserpanelconsensusbasedclinicalrecommendations AT victorllorenc fluocinoloneacetonide02μgdayintravitrealimplantinnoninfectiousuveitisaffectingtheposteriorsegmenteuexpertuserpanelconsensusbasedclinicalrecommendations AT tomasburke fluocinoloneacetonide02μgdayintravitrealimplantinnoninfectiousuveitisaffectingtheposteriorsegmenteuexpertuserpanelconsensusbasedclinicalrecommendations AT vandanogueira fluocinoloneacetonide02μgdayintravitrealimplantinnoninfectiousuveitisaffectingtheposteriorsegmenteuexpertuserpanelconsensusbasedclinicalrecommendations AT laurentkodjikian fluocinoloneacetonide02μgdayintravitrealimplantinnoninfectiousuveitisaffectingtheposteriorsegmenteuexpertuserpanelconsensusbasedclinicalrecommendations AT bahrambodaghi fluocinoloneacetonide02μgdayintravitrealimplantinnoninfectiousuveitisaffectingtheposteriorsegmenteuexpertuserpanelconsensusbasedclinicalrecommendations |